Beximco Pharmaceuticals PLC. (DSE:BXPHARMA)
Bangladesh · Delayed Price · Currency is BDT 148.40
-1.00 (-0.67%)
At close: Sep 24, 2026
DSE:BXPHARMA Ratios and Metrics
Market cap in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 66,203 | 38,410 | 52,686 | 65,222 | 68,969 | 79,096 | |
Market Cap Growth | 29.27% | -27.10% | -19.22% | -5.43% | -12.80% | 181.83% |
Enterprise Value | 67,630 | 45,704 | 62,322 | 79,259 | 84,113 | 87,267 |
Last Close Price | 148.40 | 83.39 | 108.73 | 131.37 | 135.61 | 153.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | 7.65 | 5.53 | 9.04 | 14.14 | 13.46 | 15.43 |
Forward PE | 7.64 | 6.78 | 8.62 | 12.08 | 10.83 | 16.20 |
PS Ratio | 1.23 | 0.78 | 1.19 | 1.66 | 1.99 | 2.68 |
PB Ratio | 1.03 | 0.67 | 1.01 | 1.37 | 1.55 | 2.12 |
P/TBV Ratio | 1.21 | 0.81 | 1.24 | 1.70 | 1.96 | 2.25 |
P/FCF Ratio | 9.14 | 8.65 | 8.27 | 17.75 | 28.75 | 22.58 |
P/OCF Ratio | 6.32 | 5.32 | 6.30 | 10.72 | 13.23 | 13.13 |
PEG Ratio | - | 0.30 | 0.45 | 0.64 | 0.68 | 0.98 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 1.25 | 0.93 | 1.40 | 2.02 | 2.43 | 2.96 |
EV/EBITDA Ratio | 5.12 | 4.12 | 6.06 | 8.84 | 10.20 | 11.70 |
EV/EBIT Ratio | 5.97 | 4.87 | 7.52 | 11.48 | 12.78 | 13.75 |
EV/FCF Ratio | 9.34 | 10.29 | 9.78 | 21.57 | 35.06 | 24.92 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 0.05 | 0.09 | 0.12 | 0.22 | 0.28 | 0.20 |
Debt / EBITDA Ratio | 0.24 | 0.44 | 0.59 | 1.18 | 1.50 | 1.02 |
Debt / FCF Ratio | 0.44 | 1.12 | 0.95 | 2.89 | 5.16 | 2.18 |
Net Debt / Equity Ratio | -0.04 | 0.04 | 0.09 | 0.20 | 0.25 | 0.18 |
Net Debt / EBITDA Ratio | -0.20 | 0.20 | 0.47 | 1.04 | 1.35 | 0.92 |
Net Debt / FCF Ratio | -0.36 | 0.49 | 0.75 | 2.53 | 4.62 | 1.95 |
Asset Turnover | 0.70 | 0.69 | 0.64 | 0.58 | 0.59 | 0.58 |
Inventory Turnover | 1.86 | 1.93 | 1.87 | 1.77 | 1.91 | 2.03 |
Quick Ratio | 1.40 | 0.77 | 0.52 | 0.37 | 0.35 | 0.39 |
Current Ratio | 4.13 | 2.83 | 2.18 | 1.57 | 1.45 | 1.47 |
Return on Equity (ROE) | 14.71% | 12.84% | 11.79% | 9.81% | 12.19% | 14.72% |
Return on Assets (ROA) | 9.22% | 8.23% | 7.48% | 6.38% | 6.95% | 7.75% |
Return on Invested Capital (ROIC) | 14.31% | 12.58% | 11.38% | 9.13% | 9.84% | 11.84% |
Return on Capital Employed (ROCE) | 15.80% | 14.50% | 13.90% | 12.30% | 12.30% | 14.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 23, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | 13.07% | 18.07% | 11.06% | 7.07% | 7.43% | 6.48% |
FCF Yield | 10.94% | 11.56% | 12.09% | 5.63% | 3.48% | 4.43% |
Dividend Yield | 3.20% | 5.70% | 3.68% | 2.66% | 2.58% | 2.29% |
Payout Ratio | 2.45% | 23.10% | 27.21% | 33.98% | 31.68% | 11.28% |
Total Shareholder Return | 3.20% | 5.70% | 3.68% | 2.66% | 2.58% | 2.29% |